{"id":"carmustine-bcnu","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (thrombocytopenia, leukopenia)"},{"rate":"40-60","effect":"Nausea and vomiting"},{"rate":"5-10","effect":"Pulmonary fibrosis (delayed, cumulative)"},{"rate":"10-20","effect":"Hepatotoxicity"},{"rate":"5-15","effect":"Nephrotoxicity"},{"rate":null,"effect":"Secondary malignancy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carmustine works by alkylating DNA at multiple sites, forming inter- and intra-strand cross-links that disrupt DNA replication and transcription. This leads to cell cycle arrest and apoptosis in rapidly dividing cells. It is lipophilic and can cross the blood-brain barrier, making it particularly useful for CNS malignancies.","oneSentence":"Carmustine is a nitrosourea alkylating agent that cross-links DNA strands, preventing cell replication and inducing cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:44:07.235Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Brain tumors (glioblastoma, high-grade gliomas)"},{"name":"Lymphomas"},{"name":"Leukemias"}]},"trialDetails":[{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT06915246","phase":"PHASE2","title":"A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma","status":"RECRUITING","sponsor":"VIVUS LLC","startDate":"2025-03-12","conditions":"Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":49},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT01011920","phase":"PHASE2","title":"Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-11","conditions":"Central Nervous System Lymphoma","enrollment":227},{"nctId":"NCT05540340","phase":"PHASE1","title":"A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-09","conditions":"Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell","enrollment":39},{"nctId":"NCT07448480","phase":"","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma","enrollment":1000},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT05432635","phase":"PHASE1","title":"Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-01","conditions":"B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma","enrollment":15},{"nctId":"NCT01511562","phase":"PHASE2","title":"Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2012-09","conditions":"Lymphoma","enrollment":113},{"nctId":"NCT04150042","phase":"PHASE1","title":"SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells","status":"RECRUITING","sponsor":"General Oncology, Inc.","startDate":"2021-01-13","conditions":"Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation","enrollment":24},{"nctId":"NCT02896582","phase":"PHASE2","title":"Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2016-11-29","conditions":"Mantle Cell Lymphoma","enrollment":86},{"nctId":"NCT05083754","phase":"PHASE1","title":"Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-08-31","conditions":"Glioblastoma Multiforme","enrollment":50},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT05521984","phase":"PHASE1","title":"Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-04-03","conditions":"Pediatric Brain Tumor, Pediatric Solid Tumor","enrollment":20},{"nctId":"NCT04871607","phase":"PHASE2","title":"Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-02","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":33},{"nctId":"NCT01840566","phase":"PHASE1","title":"High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-04","conditions":"Non-Hodgkin's Lymphoma","enrollment":17},{"nctId":"NCT06626516","phase":"PHASE1, PHASE2","title":"Tebentafusp-tebn With LDT in Metastatic UM","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-15","conditions":"Metastatic Uveal Melanoma","enrollment":109},{"nctId":"NCT02570542","phase":"PHASE2","title":"Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-10","conditions":"Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":59},{"nctId":"NCT05052957","phase":"PHASE2","title":"hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2023-01-20","conditions":"Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma","enrollment":16},{"nctId":"NCT02684838","phase":"","title":"Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2016-04-26","conditions":"CNS Tumor","enrollment":272},{"nctId":"NCT03125642","phase":"PHASE2","title":"Auto Stem Cell Transplant for Lymphoma Patients","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-04-20","conditions":"Non-Hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":150},{"nctId":"NCT06687772","phase":"PHASE2","title":"CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-01-16","conditions":"Diffuse Large B Cell Lymphoma","enrollment":36},{"nctId":"NCT01908777","phase":"PHASE2","title":"A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-07-16","conditions":"T Cell Non-Hodgkin Lymphoma","enrollment":47},{"nctId":"NCT07199296","phase":"PHASE2","title":"Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-07-01","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":45},{"nctId":"NCT04728633","phase":"PHASE2","title":"Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-09-27","conditions":"Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8","enrollment":28},{"nctId":"NCT02278796","phase":"PHASE2","title":"A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2015-04","conditions":"Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell","enrollment":108},{"nctId":"NCT02329080","phase":"PHASE2","title":"New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2014-12","conditions":"Diffuse Large B-cell Lymphoma","enrollment":79},{"nctId":"NCT03713580","phase":"PHASE1","title":"Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2019-03-12","conditions":"Non-hodgkin Lymphoma","enrollment":25},{"nctId":"NCT06377540","phase":"PHASE2","title":"MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-12-04","conditions":"Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma","enrollment":28},{"nctId":"NCT03583424","phase":"PHASE1, PHASE2","title":"Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":19},{"nctId":"NCT00641381","phase":"PHASE1","title":"Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2000-05-10","conditions":"Lymphoma","enrollment":25},{"nctId":"NCT02797470","phase":"PHASE1, PHASE2","title":"Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2016-06-23","conditions":"HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma","enrollment":11},{"nctId":"NCT05427136","phase":"","title":"Early Pulmonary Dysfunction in Childhood Cancer Patients","status":"RECRUITING","sponsor":"University Children's Hospital Basel","startDate":"2021-06-01","conditions":"Pulmonary Dysfunction","enrollment":140},{"nctId":"NCT01476839","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2012-11-09","conditions":"Recurrent Adult Hodgkin Lymphoma","enrollment":25},{"nctId":"NCT02342782","phase":"PHASE1","title":"Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-06-08","conditions":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03382977","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects","status":"RECRUITING","sponsor":"VBI Vaccines Inc.","startDate":"2017-12-06","conditions":"Glioblastoma Multiforme","enrollment":98},{"nctId":"NCT04222062","phase":"PHASE2","title":"A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2020-11-06","conditions":"Brain Tumor - Metastatic","enrollment":100},{"nctId":"NCT04421378","phase":"PHASE1, PHASE2","title":"A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-06-08","conditions":"Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT05221645","phase":"PHASE2","title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southampton","startDate":"2022-06-27","conditions":"Diffuse Large B Cell Lymphoma","enrollment":65},{"nctId":"NCT06652139","phase":"PHASE2","title":"Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-11-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":82},{"nctId":"NCT06652165","phase":"PHASE2","title":"Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-11-01","conditions":"DLBCL","enrollment":66},{"nctId":"NCT03217643","phase":"PHASE2","title":"CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.","status":"COMPLETED","sponsor":"Imagine Institute","startDate":"2018-02-07","conditions":"Enteropathy Associated T-cell Lymphoma","enrollment":14},{"nctId":"NCT02085304","phase":"PHASE1, PHASE2","title":"Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM","status":"TERMINATED","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2013-05-07","conditions":"Glioblastoma","enrollment":8},{"nctId":"NCT00968760","phase":"PHASE1","title":"CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-06-20","conditions":"Lymphoma, B-cell Lymphoma","enrollment":34},{"nctId":"NCT01827605","phase":"PHASE3","title":"A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-01","conditions":"Relapsed Follicular Lymphoma","enrollment":159},{"nctId":"NCT03072771","phase":"PHASE1","title":"Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-08-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":14},{"nctId":"NCT05029206","phase":"","title":"Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-05-05","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":174},{"nctId":"NCT01035463","phase":"PHASE1, PHASE2","title":"Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2009-11-12","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":74},{"nctId":"NCT00574509","phase":"PHASE1","title":"Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"1996-03-04","conditions":"Lymphoma","enrollment":34},{"nctId":"NCT00080886","phase":"PHASE2","title":"Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2002-05-08","conditions":"Lymphoma","enrollment":68},{"nctId":"NCT00610883","phase":"PHASE2","title":"LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1990-05","conditions":"Non-Hodgkin's Lymphoma","enrollment":17},{"nctId":"NCT00571493","phase":"PHASE1, PHASE2","title":"VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-04-14","conditions":"Non-hodgkin's Lymphoma, Mantle Cell Lymphoma","enrollment":42},{"nctId":"NCT00572013","phase":"PHASE1, PHASE2","title":"Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"1998-05-12","conditions":"Lymphoma","enrollment":32},{"nctId":"NCT00007852","phase":"PHASE2","title":"Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2000-09-01","conditions":"Lymphoma","enrollment":44},{"nctId":"NCT00006695","phase":"PHASE2","title":"Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2000-04-01","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT05931263","phase":"PHASE3","title":"A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-06-01","conditions":"Newly Diagnosed Peripheral T-cell Lymphoma","enrollment":104},{"nctId":"NCT05922384","phase":"NA","title":"Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With Lymphoma","status":"RECRUITING","sponsor":"Affiliated Hospital of Guangdong Medical University","startDate":"2023-07-05","conditions":"HIV Infections, Lymphoma","enrollment":3},{"nctId":"NCT05863845","phase":"NA","title":"Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2023-06-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":52},{"nctId":"NCT05814718","phase":"NA","title":"Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-04-15","conditions":"Autologous Stem Cell Transplantation, Conditioning","enrollment":122},{"nctId":"NCT03019640","phase":"PHASE2","title":"Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-10","conditions":"Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma","enrollment":22},{"nctId":"NCT05228249","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-04","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":""},{"nctId":"NCT00096460","phase":"PHASE2, PHASE3","title":"Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2004-08","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":30},{"nctId":"NCT01141712","phase":"PHASE2","title":"Autologous Transplant in HIV Patients (BMT CTN 0803)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2010-04","conditions":"Lymphoma, HIV","enrollment":43},{"nctId":"NCT03591861","phase":"NA","title":"Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2019-05-01","conditions":"Pediatric Brain Tumor","enrollment":2},{"nctId":"NCT05367856","phase":"PHASE2","title":"Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2022-05-28","conditions":"T Cell Lymphoma","enrollment":23},{"nctId":"NCT05518383","phase":"PHASE4","title":"B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-05-25","conditions":"Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma, Primary Mediastinal Lymphoma","enrollment":300},{"nctId":"NCT05466318","phase":"PHASE3","title":"ChiCGB vs BEAM in High-risk or R/R Lymphomas","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2022-07-01","conditions":"Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell","enrollment":306},{"nctId":"NCT03736616","phase":"PHASE2","title":"Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL","status":"UNKNOWN","sponsor":"Swedish Medical Center","startDate":"2019-08-16","conditions":"Diffuse Large B Cell Lymphoma","enrollment":47},{"nctId":"NCT03570983","phase":"PHASE2","title":"A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion","status":"UNKNOWN","sponsor":"Swedish Medical Center","startDate":"2018-09-05","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT05425654","phase":"PHASE2","title":"RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"National Research Center for Hematology, Russia","startDate":"2021-05-17","conditions":"Primary CNS Lymphoma","enrollment":30},{"nctId":"NCT00712582","phase":"PHASE2","title":"Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-07-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":96},{"nctId":"NCT05398224","phase":"PHASE2","title":"R-MTX-zanbrutinib in Secondary CNS Lymphoma","status":"UNKNOWN","sponsor":"Peking University","startDate":"2021-02-26","conditions":"Secondary Central Nervous System Lymphoma","enrollment":45},{"nctId":"NCT00669669","phase":"PHASE1, PHASE2","title":"O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02-25","conditions":"Glioblastoma, Gliosarcoma","enrollment":12},{"nctId":"NCT03629873","phase":"PHASE2","title":"Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-02-01","conditions":"Lymphoma, Large B-Cell, Diffuse, Mantle Cell Lymphoma, Peripheral T Cell Lymphoma","enrollment":69},{"nctId":"NCT05075681","phase":"PHASE1, PHASE2","title":"Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-11-01","conditions":"Peripheral Blood Stem Cell Transplantation","enrollment":50},{"nctId":"NCT05088226","phase":"PHASE2","title":"Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-12-01","conditions":"Peripheral Blood Stem Cell Transplantation","enrollment":50},{"nctId":"NCT00350181","phase":"PHASE2","title":"Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT","status":"COMPLETED","sponsor":"Stanford University","startDate":"2006-08","conditions":"Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases","enrollment":11},{"nctId":"NCT00536601","phase":"NA","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2006-06-29","conditions":"Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","enrollment":174},{"nctId":"NCT02059239","phase":"PHASE1, PHASE2","title":"Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2014-06-04","conditions":"Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT04755023","phase":"PHASE2","title":"Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2005-12-21","conditions":"Oligodendroglioma; Oligoastrocytoma","enrollment":53},{"nctId":"NCT00591630","phase":"PHASE2","title":"Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-11-14","conditions":"Diffuse Large Cell Lymphoma, Lymphoma","enrollment":30},{"nctId":"NCT00004031","phase":"PHASE3","title":"SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1997-07","conditions":"Lymphoma","enrollment":397},{"nctId":"NCT02504359","phase":"PHASE1","title":"Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2015-07-20","conditions":"Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma","enrollment":11},{"nctId":"NCT02483000","phase":"PHASE1","title":"Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2017-02-01","conditions":"Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present, Diffuse Large B-Cell Lymphoma","enrollment":3},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00006386","phase":"PHASE2","title":"Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2001-03","conditions":"Brain and Central Nervous System Tumors","enrollment":80},{"nctId":"NCT04582604","phase":"PHASE1, PHASE2","title":"Ruxolitinib and Decitabine for High Risk Hematological Malignancies","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Peripheral Blood Stem Cell Transplantation","enrollment":60},{"nctId":"NCT00536978","phase":"PHASE2","title":"Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-09","conditions":"Lymphoma, Leukemia","enrollment":22},{"nctId":"NCT01921387","phase":"PHASE1, PHASE2","title":"Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-10-09","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":20},{"nctId":"NCT00345865","phase":"PHASE2","title":"Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-08-24","conditions":"Lymphoma","enrollment":473},{"nctId":"NCT00795665","phase":"PHASE2","title":"Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2008-06","conditions":"Glioma","enrollment":7},{"nctId":"NCT00632827","phase":"PHASE2","title":"Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-07-01","conditions":"Peripheral T-Cell Lymphoma","enrollment":21},{"nctId":"NCT00992446","phase":"PHASE2","title":"Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-09-02","conditions":"Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":27},{"nctId":"NCT00525590","phase":"PHASE2","title":"Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-12-12","conditions":"Metastatic Brain Cancer","enrollment":69},{"nctId":"NCT00005803","phase":"PHASE1, PHASE2","title":"Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"1999-09","conditions":"Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma","enrollment":76},{"nctId":"NCT03579927","phase":"PHASE1, PHASE2","title":"CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-03","conditions":"CD19 Positive, Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT00342316","phase":"NA","title":"Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2003-12-18","conditions":"Acute Myeloid Leukemia","enrollment":340},{"nctId":"NCT02670109","phase":"PHASE2","title":"Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2018-02-01","conditions":"Triple-Negative Invasive Breast Carcinoma, Residual Tumor","enrollment":20},{"nctId":"NCT00984438","phase":"PHASE1, PHASE2","title":"Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme","status":"WITHDRAWN","sponsor":"University of Cincinnati","startDate":"2009-06","conditions":"Glioblastoma Multiforme","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":469,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Carmustine BCNU","genericName":"Carmustine BCNU","companyName":"Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie","companyId":"gruppo-italiano-multiregionale-per-lo-studio-dei-linfomi-e-delle-leucemie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carmustine is a nitrosourea alkylating agent that cross-links DNA strands, preventing cell replication and inducing cancer cell death. Used for Brain tumors (glioblastoma, high-grade gliomas), Lymphomas, Leukemias.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}